Aplastic Anemia

Consider Allogeneic Bone Marrow Transplantation for Older, Fit Patients with Aplastic Anemia

Effective treatment for severe aplastic anemia (SAA) is either allogeneic bone marrow transplantation (BMT) [1,2] or nontransplant immunosuppressive therapy (IST) containing antithymocyte globulin (ATG) [3,4]. Both treatment approaches have advanced over the recent decades to achieve significantly improved outcomes.

Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia

Our study aimed to compare treatment outcomes between hematopoietic stem cell transplantation (HSCT) from haploidentical donors (HID) and immunosuppressive therapy (IST) in adults with acquired severe aplastic anemia (SAA). The medical records of 113 SAA adults who received IST, including rabbit ATG and cyclosporin (N = 37), or HID HSCT (N = 76) within 6 months of diagnosis at two institutions were retrospectively reviewed. Estimated 8-year overall survival (OS) was comparable between the IST and HID HSCT groups (75.6 vs.

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.